| doxercalciferol / Generic mfg. |
NCT00135304: ACHIEVE: Optimizing the Treatment of Secondary Hyperparathyroidism |
|
|
| Completed | 4 | 170 | US | Sensipar®, Cinacalcet hydrochloride, Cinacalcet HCL, Cinacalcet, Vitamin D, paricalcitol, doxercalciferol | Amgen | Secondary Hyperparathyroidism | 10/06 | 12/06 | | |
NCT00418600: A Phase 4, Conversion Study of Hectorol® Injection to Hectorol® Capsules in Stage 5 CKD Patients on Dialysis |
|
|
| Completed | 4 | 36 | US | Hectorol® (doxercalciferol capsules), doxercalciferol capsules, Hectorol®, doxercalciferol capsules, Hectorol® capsules | Genzyme, a Sanofi Company | Secondary Hyperparathyroidism | 06/07 | 08/07 | | |
NCT00454350: A Phase 4 Pharmacokinetic Study of Hectorol Injection and Zemplar Injection in CKD Subjects on Hemodialysis |
|
|
| Completed | 4 | 12 | US | Hectorol (doxercalciferol injection), Zemplar (Paricalcitol injection) | Genzyme, a Sanofi Company | Secondary Hyperparathyroidism | | 07/07 | | |
NCT00123461: Study of Safety and Efficacy of Doxercalciferol in Patients With Chronic Kidney Disease, Stage 3 or 4, and Secondary Hyperparathyroidism |
|
|
| Completed | 4 | 70 | US | Hectorol (doxercalciferol capsules), 0.5mcg | Genzyme, a Sanofi Company | Secondary Hyperparathyroidism, Renal Failure, Chronic Renal Insufficiency | 10/07 | 10/07 | | |
NCT00463021: A Phase 4 Study to Determine Dosing of Hectorol® Capsules When Converting From Zemplar® Injection |
|
|
| Completed | 4 | 36 | US | Hectorol (doxercalciferol capsules), Zemplar (paricalcitol injection) | Genzyme, a Sanofi Company | Secondary Hyperparathyroidism | | 12/07 | | |
NCT00257920: A Study of Zemplar® Injection and Hectorol® Injection on Intestinal Absorption of Calcium in Chronic Kidney Disease |
|
|
| Completed | 4 | 41 | US | Zemplar® injection, ABT-358, paricalcitol, Zemplar, Hectorol® injection, Hectorol® | Abbott | Chronic Kidney Disease, Stage 5, Secondary Hyperparathyroidism | 01/08 | | | |
NCT00502268: Vitamin D and Carboxy PTH Fragments in Coronary Calcification |
|
|
| Withdrawn | 4 | 0 | US | Doxercalciferol administration, Doxercalciferol administered by 1-84-7-84 | Southeast Renal Research Institute | Coronary Calcification, Endstage Renal Disease, Parathyroid Hormone | 02/09 | 07/09 | | |
NCT00646282: Mineral Metabolism and Vascular Effects of Vitamin D Therapy in Kidney Transplant Patients |
|
|
| Terminated | 4 | 12 | US | doxercalciferol, Hectorol | Emory University | Hyperparathyroidism, Secondary | 01/10 | 01/10 | | |
NCT00889629: Pilot Study Evaluating Doxercalciferol Replacement Therapy in Kidney Transplant Recipients |
|
|
| Completed | 4 | 39 | US | Doxercalciferol, Hectorol (the other name for Doxercalciferol), placebo, Placebo for doxercalciferol, 25-OH Vitamin D3, (cholecalciferol) | Mariana Markell, Genzyme, a Sanofi Company | Chronic Kidney Disease, Kidney Transplantation | 01/10 | 01/10 | | |
| Completed | 4 | 272 | US, Europe, RoW | Paricalcitol, ABT-358, Zemplar, Cinacalcet, Sensipar, Mimpara, Hectorol | Abbott | Chronic Kidney Disease, Secondary Hyperparathyroidism, Hemodialysis | 05/11 | 05/11 | | |
|
|
|
|
|
|
NCT00749736: The Role of Vitamin D in Immune Function in Patients With Chronic Kidney Disease (CKD) Stages 3 and 4. |
|
|
| Completed | 4 | 100 | US | cholecalciferol, doxercalciferol, placebo | Indiana University | Chronic Kidney Disease | 07/12 | 07/12 | | |
NCT00528788: How Vitamin D Analogues Affect Endothelial Cells in Patients on Dialysis |
|
|
| Completed | 4 | 24 | US | doxercalciferol | Duke University, Genzyme, a Sanofi Company | Hyperparathyroidism, Secondary, Kidney Failure, Chronic | 08/12 | 08/12 | | |
